Keyphrases
Phase II Trial
100%
Papillomavirus Infections
100%
Carraguard
100%
High-risk Human Papillomavirus (HR-HPV)
72%
Cervical Cancer
18%
Bronx
18%
Population Council
18%
Cervicovaginal Lavage
18%
School of Medicine
18%
Albert Einstein
18%
Medical Center
18%
New Humanities
9%
Abnormal Pap Test
9%
Microbicides
9%
Vaginal Microbiome
9%
Seminal Plasma
9%
Further Development
9%
Animal Model Study
9%
Vaginal Microbicides
9%
Jacobi
9%
Combination Microbicide
9%
One Year Period
9%
Female Genital Tract
9%
Infection Prevention
9%
Public Hospitals
9%
Efficacy Trial
9%
Randomized Double-blind Placebo-controlled Study
9%
Pseudovirion
9%
Genital Tract
9%
Anti-HIV Agents
9%
Early Adoption
9%
Effective Combination
9%
Formulation Vehicle
9%
Repeated Application
9%
HIV Infection in Women
9%
Cervical Intraepithelial Neoplasia
9%
Sexually Transmitted Infection Prevention
9%
Mechanism of Activity
9%
Manhattan
9%
Clinical Trials
9%
Shared Vision
9%
Placebo Groups
9%
Vaginal Swab
9%
University Hospital
9%
New York
9%
Antiviral Activity
9%
HIV Infection
9%
Medicine and Dentistry
Carrageenan
100%
Phase II Trials
100%
Papillomavirus Infection
100%
Wart Virus
72%
Antimicrobial Agent
27%
Cervical Cancer
18%
Population Council
18%
Lavage
18%
Human Immunodeficiency Virus Infection
18%
Medicine
18%
Human Immunodeficiency Virus
18%
Papanicolaou Stain
9%
Secretion (Process)
9%
Infection Prevention
9%
Cervical Intraepithelial Neoplasia
9%
Seminal Plasma
9%
Placebo
9%
Anti Human Immunodeficiency Virus Agent
9%
Antiviral Activity
9%
Arm
9%
Placebo-Controlled Study
9%
Ex Vivo
9%
In Vitro
9%
Clinical Trial
9%
Pharmacology, Toxicology and Pharmaceutical Science
Phase II Trials
100%
Carrageenan
100%
Papillomavirus Infection
100%
Human Papillomavirus
72%
Antimicrobial Agent
27%
Uterine Cervix Cancer
18%
HIV
18%
Human Immunodeficiency Virus Infection
18%
Vagina Flora
9%
Antiviral Activity
9%
Anti Human Immunodeficiency Virus Agent
9%
Uterine Cervix Carcinoma in Situ
9%
Clinical Trial
9%
Placebo
9%
Placebo-Controlled Study
9%